News room
Miguel Garcia speaks at Ciência 2021, an event promoted by Portuguese Foudation for Science and Technology
Technophage's CEO, Miguel Garcia, attended the "Encontro Ciência 2021" in the last 30 of June, speaking about the company's journey at the plenary...
Technophage is hiring a lab technician
TechnoPhage is hiring a Laboratory Technician to support research activities and conduct laboratory tasks within a team dedicated to the research...
Technophage announces FDA Fast Track Designation Granted to TP-102 for the treatment of patients with infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii
Technophage announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TP-102, the company’s first...
Interview to Link to Leaders by Miguel Garcia, CEO of Technophage
In the past few months, and due to the recently initiated Phase I/IIa Clinical Trial of the bacteriophage cocktail TP-102, which has been entirely...
The radiopharmaceutical way to diagnose Alzheimer’s Disease
In a joint effort to tackle Alzheimer's Disease (AD), Technophage in collaboration with ICNAS (Instituto de Ciências Nucleares Aplicadas à Saúde) is...